Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption

Related articles

1. Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition

   This article has 17 authors:

   1. Ana Orive-Ramos
   2. Bijaya Gaire
   3. Christos Adamopoulos
   4. Beau Baars
   5. Mathieu Desaunay
   6. Ziyue Kou
   7. Evangelia Matenoglou
   8. Silvia Coma
   9. Nayeli Gutiérrez-Trejo
   10. Kevin Mohammed
   11. Stuart A. Aaronson
   12. Jian Jin
   13. Tiphaine C. Martin
   14. Ernesto Guccione
   15. Evripidis Gavathiotis
   16. Jonathan A. Pachter
   17. Poulikos I. Poulikakos

2. Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma

   This article has 11 authors:

   1. Yeon-Hwa Lee
   2. Christophe Cataisson
   3. Haibo Zhang
   4. Snehal Gaikwad
   5. Wendy D. du Bois
   6. Aleksandra M. Michalowski
   7. Howard H. Yang
   8. Thomas J. Meyer
   9. Ryan M. Young
   10. Beverly A. Mock
   11. Ji Luo

3. Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven Cancer

   This article has 17 authors:

   1. Fredrik I. Thege
   2. Annaliese Kramer
   3. Norbert Kreisz
   4. Intisar Salim
   5. Etsehiwot Girum Girma
   6. Linara Welte
   7. Elizabeth Adams
   8. Ashton Pluchinsky
   9. Elijah Kirschstein
   10. Olivia Harder
   11. Amber Hoskins
   12. Ashwath Seetharaman
   13. Kimal Rajapakshe
   14. Yuki Makino
   15. Andrew J. Gunderson
   16. Sonja M. Wörmann
   17. Anirban Maitra